Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2014) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

(2013) Barry J. Maurer et al.   PEDIATRIC BLOOD & CANCER

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

(2011) Jason P Cooper et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group

(2011) J. G. Villablanca et al.   CLINICAL CANCER RESEARCH

High-Dose Fenretinide in Oral Leukoplakia

(2009) W. N. William et al.   Cancer Prevention Research

Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial

(2009) Eric Cheung et al.   Clinical Genitourinary Cancer

Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer

(2008) A. L. Sabichi et al.   CLINICAL CANCER RESEARCH